Hematopoietic Stem Cell Transplantation for Hepatitis-associated Aplastic Anemia Following Liver Transplantation for Nonviral Hepatitis: A Retrospective Analysis and a Review of the Literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation
Hepatitis-associated aplastic anemia (HAAA) has been reported in 23% to 33% of patients who received orthotopic liver transplantation (LT) for acute liver disease of unknown origin (nonviral hepatitis). In this situation, hematopoietic stem cell transplantation (HSCT) might be a curative option. Here the authors report on 6 patients who received HSCT after LT for nonviral HAAA hepatitis. The outcomes were interpreted in the context of recently reported immune suppressive therapy (IST) outcomes in 8 patients with HAAA and to HSCT outcomes in patients with HAAA who recovered from hepatitis without undergoing LT. All patients transplanted by using HLA-identical sibling donors (3 of 6) were alive and had normal liver function and hematopoiesis without graft versus host disease. Both patients receiving bone marrow from a matched unrelated donor (MUD) experienced extensive graft versus host disease that was fatal for one patient. Thereby, the authors conclude that HSCT can be considered as a first-choice treatment for this category of patients when HLA-identical donors are available. When no HLA-identical donor is available, IST should be applied as HSCT with other donor sources might be reserved for IST nonresponders or poor responders.
In this study, we use weight independent and microbiome transplant SG models to determine whether increase in natural IgM requires weight loss or the microbiome.
Worldwide, healthcare systems were challenged during the COVID-19 pandemic. Tertiary hospitals, which perform the majority of organ transplants in Mexico, shifted gears to provide treatment for critically ill COVID-19 patients.
We present a novel pre-clinical rodent model of AA treated with human placental stem cells (hPSC), their anti-inflammatory products (conditioned media, CM) and barrier hydrogel therapies for adhesion prevention.
Acute care surgery (ACS) in patients with end-stage liver disease (ESLD) is associated with a high morbidity and mortality.
Endothelial glycocalyx (EGX) damage occurs in various pathological states and results in endotheliopathy. Exosomes (ES) and Microvesicles (MS) isolated from adipose-derived mesenchymal stem cells (ASCs) have therapeutic potential. We hypothesized that ASC-derived ES and MS would not affect EGX shedding after injury.
For patients with severe portal vein thrombosis (PVT), an SMV conduit is usually considered the primary reconstruction option. A left gastric varix (LGV) conduit reconstruction is an alternative which we prefer because it requires less dissection and has less risk of tension and torsion. The aim of this study was to compare the outcomes of patients using an SMV conduit to those using a gastric varix conduit.
Thromboelastography (TEG) has emerged as a tool to guide resuscitation in Liver Transplantation (LT). We aim to identify effects of TEG utilization on product use and blood loss in LT.
The obesity epidemic in the United States has led to increasing proportion of obese liver transplant (LT) recipients. Previous studies have not found significant differences in graft survival (GS) and patient survival (PS) between obese and non-obese recipients. However, obesity is a complex, socioeconomic disease that is intrinsically tied with race. Thus, the aim of this work was to analyze the effects of race on liver transplant outcomes in obese recipients.
We examined actual weight and weight perception among pre-liver transplant patients.
Cardiac risk stratification is a routine step in the workup of patients awaiting organ transplant. Currently, there is limited data regarding the outcomes of patients undergoing cardiac revascularization to achieve transplant candidacy, particularly in patients receiving percutaneous coronary intervention (PCI). We investigated the outcomes of potential transplant candidates who underwent PCI and assessed their post-intervention outcomes.